NCT06437639

MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

Prospective, Open, Comparative, Randomized Study of the Efficacy and Safety Evaluation of the Mexidol® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 80 (actual)
• Sponsor: Pharmasoft · Industry
• Sex: All
• Age: 50 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Hypothesis: The use of neurocytoprotectors helps restore the functional activity of mitochondria, improve the nervous activity of the retina and optic nerve, and stabilize the glaucomatous process.

Detailed description

Hypothesis: Mexidol® allows to optimize POAG therapy by reducing mitochondrial dysfunction and stabilizing glaucomatous optic neuropathy by improving the functional activity of mitochondria and its energy-producing function

Conditions

• Primary Open-Angle Glaucoma (POAG)

Interventions

Type	Name	Description
DRUG	Mexidol	Neurocytoprotector

Timeline

• Start date: 2023-09-15
• Primary completion: 2023-11-29
• Completion: 2024-02-02
• First posted: 2024-05-31
• Last updated: 2025-12-12

Locations

1 site across 1 country: Russia